4-(beta-Arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidinols and related compounds: a novel class of cytotoxic and anticancer agents. 1998

J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
College of Pharmacy and Nutrition, Department of Chemistry, and Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada.

The syntheses of a series of 1-aryl-5-diethylamino-1-penten-3-one hydrochlorides 1 and 1-aryl-3-diethylamino-1-propanone hydrochlorides 4 were accomplished. Attempts to prepare the corresponding bis(5-aryl-3-oxo-4-pentenyl)ethylamine hydrochlorides 2 and bis(3-aryl-3-oxopropyl)ethylamine hydrochlorides 5 led to the formation of a series of 4-(beta-arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidi nol hydrochlorides 9 and 4-aryl-3-arylketo-1-ethyl-4-piperidinol hydrochlorides 11, most of which were converted subsequently into the corresponding quaternary ammonium salts 10 and 12, respectively. The structures of these compounds were determined by 1H NMR spectroscopy and confirmed by X-ray crystallography of representative molecules. Most compounds displayed significant cytotoxicity toward murine P388 and L1210 cells as well as human tumors. In general, Mannich bases containing olefinic bonds were more cytotoxic than the analogues without this functional group, while the piperidines 9 and 11 were more potent than the acyclic analogues 1 and 4, respectively. Correlations were noted between various physicochemical constants in the aryl rings and cytotoxicity. Compound 9d displayed promising in vivo activity against colon cancers. This study has revealed that the piperidines 9 and 11 constitute new classses of cytotoxic agents.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008352 Mannich Bases Ketonic amines prepared from the condensation of a ketone with formaldehyde and ammonia or a primary or secondary amine. A Mannich base can act as the equivalent of an alpha,beta unsaturated ketone in synthesis or can be reduced to form physiologically active amino alcohols. Mannich Base,Base, Mannich,Bases, Mannich
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D010880 Piperidines A family of hexahydropyridines.
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
November 1969, Journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
June 1960, Journal of medicinal and pharmaceutical chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
June 2013, Mini reviews in medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
December 2008, Acta pharmacologica Sinica,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
July 1973, Journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
December 2002, European journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
May 1968, Journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
July 1963, Journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
September 1968, Journal of medicinal chemistry,
J R Dimmock, and S C Vashishtha, and J W Quail, and U Pugazhenthi, and Z Zimpel, and A M Sudom, and T M Allen, and G Y Kao, and J Balzarini, and E De Clercq
September 1967, Journal of medicinal chemistry,
Copied contents to your clipboard!